More from ETFs
The AGFiQ U.S. Market Neutral Anti-Beta Fund managed to return 18.50% over the past quarter -- and, no, it's not an inverse or levered inverse fund.
It officially changed from concern over inflation and interest rates to fear of recession, which is causing a change in where traders position themselves.
There's a bright spot, but it needs to be sustained.
The SPDR S&P Biotech ETF is one of the better-looking charts on this trader's screen, as is an individual biotech name.
A key goal is to keep from losing money while the current bear runs its course, and don't count on positive seasonality leading to the Fourth of July.